<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Pharm Rep</journal-id><journal-id journal-id-type="iso-abbrev">Med Pharm Rep</journal-id><journal-id journal-id-type="publisher-id">Med Pharm Rep</journal-id><journal-title-group><journal-title>Medicine and Pharmacy Reports</journal-title></journal-title-group><issn pub-type="ppub">2602-0807</issn><issn pub-type="epub">2668-0572</issn><publisher><publisher-name>Iuliu Hatieganu University of Medicine and Pharmacy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9387583</article-id><article-id pub-id-type="doi">10.15386/mpr-2142</article-id><article-id pub-id-type="publisher-id">cm-95-229</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject><subj-group><subject>Dermatology</subject></subj-group></subj-group></article-categories><title-group><article-title>The prognostic significance of the clinical and histological parameters in primary cutaneous melanoma patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Antohe</surname><given-names>Mihaela</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Coman</surname><given-names>Anastasia</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Turcu</surname><given-names>Gabriela</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af2-cm-95-229" ref-type="aff">2</xref><xref rid="af3-cm-95-229" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Nedelcu</surname><given-names>Roxana Ioana</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Brinzea</surname><given-names>Alice</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Balaban</surname><given-names>Mihaela</given-names></name><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Moroianu</surname><given-names>Andreea</given-names></name><xref rid="af2-cm-95-229" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Manea</surname><given-names>Lorena</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af4-cm-95-229" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Hulea</surname><given-names>Ionela</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Balasescu</surname><given-names>Elena</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Zurac</surname><given-names>Sabina Andrada</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref><xref rid="af3-cm-95-229" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Cioplea</surname><given-names>Mirela</given-names></name><xref rid="af3-cm-95-229" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Popp</surname><given-names>Cristiana</given-names></name><xref rid="af3-cm-95-229" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Nichita</surname><given-names>Luciana</given-names></name><xref rid="af3-cm-95-229" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ion</surname><given-names>Daniela Adriana</given-names></name><xref rid="af1-cm-95-229" ref-type="aff">1</xref></contrib></contrib-group><aff id="af1-cm-95-229">
<label>1</label>&#x0201c;Carol Davila&#x0201d; University of Medicine and Pharmacy, Bucharest, Romania</aff><aff id="af2-cm-95-229">
<label>2</label>Dermatology Clinic, Derma360 Clinic, Bucharest, Romania</aff><aff id="af3-cm-95-229">
<label>3</label>Pathology Department, Colentina Clinical Hospital, Bucharest, Romania</aff><aff id="af4-cm-95-229">
<label>4</label>Dermatology Department, Colentina Clinical Hospital, Bucharest, Romania</aff><author-notes><corresp id="c1-cm-95-229">Address for correspondence: <email>anastasia.hodorogea@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>26</day><month>7</month><year>2022</year></pub-date><volume>95</volume><issue>3</issue><fpage>229</fpage><lpage>235</lpage><history><date date-type="received"><day>31</day><month>3</month><year>2021</year></date><date date-type="rev-recd"><day>17</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>31</day><month>5</month><year>2022</year></date></history><permissions><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License</license-p></license></permissions><abstract><p>Cutaneous melanoma is the most aggressive form of skin cancer and its incidence is unfortunately increasing. In the last decades, a progressive increase of new cases of diagnosed thin melanoma has been noted. This may be due to earlier detection, better surveillance, improved diagnostic criteria or increased exposure to sunlight. Despite the fact that Breslow tumor thickness has the strongest proven prognostic significance, there are still thin melanomas that metastasize and thick melanomas with favorable evolution. Therefore, the identification of strong predictive factors for survival is mandatory, particularly for patients with thin melanoma.</p></abstract><kwd-group><kwd>melanoma</kwd><kwd>thin melanoma</kwd><kwd>prognosis</kwd><kwd>survival rate</kwd><kwd>predictive factors</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Over time, there has been a significant decrease in median tumor thickness, such as from 1.8 mm in 1976 to 0.5 mm in 2000, as well as an increase of the incidence in cases of thin cutaneous melanoma (Breslow thickness &#x02264;1 mm), from 39% in 1976 to 65.5% in 2000 [<xref rid="b1-cm-95-229" ref-type="bibr">1</xref>]. Nowadays it represents approximately 70% of all diagnosed skin melanomas [<xref rid="b2-cm-95-229" ref-type="bibr">2</xref>] and accounts for 25% of all melanoma deaths [<xref rid="b3-cm-95-229" ref-type="bibr">3</xref>].</p><p>Fortunately, in most cases with thin cutaneous melanomas, surgical excision is curative and these patients have a favorable overall prognosis. Five percent of patients with this subtype of melanoma have a risk of metastasis and even death within 10 years [<xref rid="b4-cm-95-229" ref-type="bibr">4</xref>]; the overall survival rate for this group at 10-year follow-up is approximately 4.5&#x02013;8% [<xref rid="b5-cm-95-229" ref-type="bibr">5</xref>]. Therefore, the identification of strong predictive factors for metastasis and survival is mandatory, particularly for patients with thin melanoma.</p><p>Numerous studies have shown that no parameter (serological, molecular, histological or immunohistochemical) alone has an accurate predictive value for the evolution of melanoma. Thus, a combination of new factors is needed to identify patients at high risk of metastasis, which would further benefit from a more aggressive treatment plan.</p><p>The histopathological reports bring plenty of information about the prognosis of melanoma patients thus contributing to a better management and follow-up of these patients. Over time, many studies have shown that the main parameters that are associated with poor prognosis are the older age, male gender, localization of the primary tumor at the axial or head or neck level, increased Breslow and Clark indices, vertical growth phase, ulceration, increased mitotic rate, tumor regression and the absence of inflammatory infiltrate [<xref rid="b6-cm-95-229" ref-type="bibr">6</xref>&#x02013;<xref rid="b9-cm-95-229" ref-type="bibr">9</xref>].</p></sec><sec><title>Age</title><p>Most studies have shown that with age, the risk of unfavorable outcome of patients diagnosed with melanoma increases. The main reason for this is that as age increases, the thickness of the tumor grows and the risk of ulceration and regression of the tumor is higher [<xref rid="b10-cm-95-229" ref-type="bibr">10</xref>]. This happens because elderly patients are less concerned about skin changes that occur over time and tend to practice self-examination less often than young people [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>].</p><p>Several studies have shown that old age is an independent predictor of survival in melanoma patients [<xref rid="b1-cm-95-229" ref-type="bibr">1</xref>,<xref rid="b12-cm-95-229" ref-type="bibr">12</xref>].</p><p>Cutaneous melanoma in children is rare, especially before puberty. It represents 1.2% of all forms of cancer by the age of 15 years and 7% between 15 and 19 years [<xref rid="b7-cm-95-229" ref-type="bibr">7</xref>]. In a study of 354 patients aged up to 18 years with cutaneous melanoma, 80% were diagnosed over the age of 14 years [<xref rid="b13-cm-95-229" ref-type="bibr">13</xref>]. A large epidemiological study found that the mortality rate in cutaneous melanoma patients was 8 to 18 times higher in adolescent patients, with age between 15 to 19 years, compared to younger ones [<xref rid="b14-cm-95-229" ref-type="bibr">14</xref>].</p><p>In addition to age, studies have shown that the main factors that associate a decrease in overall survival in children and adolescents with melanoma are the high number of melanocytic nevi, innate immunodeficiency, increased Breslow tumor thickness and increased Clark level [<xref rid="b7-cm-95-229" ref-type="bibr">7</xref>]. It has been observed that patients with more than 100 nevi have a 34 times higher risk of developing melanoma than those with few nevi [<xref rid="b15-cm-95-229" ref-type="bibr">15</xref>]. In addition, innate immunodeficiency confers a 3&#x02013;6 times higher risk for melanoma [<xref rid="b7-cm-95-229" ref-type="bibr">7</xref>].</p><p>Interestingly, besides all these prognostic factors, some studies have shown that the prognosis of children with melanoma who had positive SLNB (SLNB - sentinel lymph node biopsy) was better than in adults [<xref rid="b16-cm-95-229" ref-type="bibr">16</xref>]. Some authors believe this is due to changes in the density of lymphatic flow related to age and in the immune system which is able to better fight malignant cells [<xref rid="b7-cm-95-229" ref-type="bibr">7</xref>,<xref rid="b17-cm-95-229" ref-type="bibr">17</xref>].</p></sec><sec><title>Gender</title><p>Numerous studies have shown that in patients with cutaneous melanoma, males have a worse prognosis compared to females. Multivariate analysis in a study of 5093 patients showed a favorable predictive role in females in terms of prognosis [<xref rid="b18-cm-95-229" ref-type="bibr">18</xref>].</p><p>Several factors have been incriminated to influence the better outcome in women, namely the location of the primary tumor, hormonal and endocrine factors, the prevalence of smoking. Most studies have shown that survival rates in women at 5 and 10-year follow-up are 10&#x02013;20% higher up to 65 years. After this age this advantage is lost [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>,<xref rid="b18-cm-95-229" ref-type="bibr">18</xref>].</p><p>Although the role of estrogens was initially invoked, this hypothesis was excluded since it has been found that melanoma does not have estrogen receptors and does not respond to anti-estrogen therapy [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>,<xref rid="b19-cm-95-229" ref-type="bibr">19</xref>].</p><p>The location of the primary tumor is an important factor in the protective role of female sex as it has been observed that the most common locations in women are the limbs. In a study conducted in Sweden on six national registries that included 12,533 patients, women presented with 53.5% extremity and 30.2% trunk melanomas, while men had 25.2% extremity and 56.7% trunk melanomas [<xref rid="b20-cm-95-229" ref-type="bibr">20</xref>]. It has been observed that in men the locations of the tumor at the level of the head and neck and the axial locations are more frequent [<xref rid="b21-cm-95-229" ref-type="bibr">21</xref>]. These are associated with a poorer prognosis.</p><p>In addition, the thickness of the tumor seems to be another important factor, as women tend to have thinner melanomas than men [<xref rid="b22-cm-95-229" ref-type="bibr">22</xref>], perhaps they have a higher addressability to doctors.</p><p>However, the protective role of female sex remains controversial. For example, another study showed that in case of thin melanomas with tumor thickness less than 1 mm, sex was not an important predictive factor [<xref rid="b23-cm-95-229" ref-type="bibr">23</xref>].</p></sec><sec><title>Location of the primary tumor</title><p>Many studies have shown a poorer prognosis for axial and head or neck lesions than for extremities. A retrospective cohort study of 51,704 patients using United States cancer registries compared the prognosis of patients with head or neck lesions to melanoma patients with other primary tumor sites. Among the conclusions of the study was that 5-year overall survival was 83.1% in patients with melanoma on the scalp or neck compared to 92.1% in those with other locations. Also the 10-year overall survival for scalp or neck melanoma was 76.2% compared to 88.7% in melanoma patients with other location. In addition, they observed that the risk of death in patients with melanoma on the head or neck was about twice higher than in patients with other locations of the primary tumor [<xref rid="b24-cm-95-229" ref-type="bibr">24</xref>].</p><p>One reason why trunk melanoma has a worse prognosis than those of the extremities is perhaps the difference in lymphatic drainage; axial tumors can drain to the mediastinal or para-aortic lymph nodes but also to inguinal or axillary areas [<xref rid="b25-cm-95-229" ref-type="bibr">25</xref>].</p></sec><sec><title>Breslow tumor thickness</title><p>The maximum thickness of the tumor is measured from the granular layer or from the base of the ulceration, if the tumor is ulcerated, to the deepest area of invasion. It was first defined as having prognostic significance by pathologist Alexander Breslow in 1970 [<xref rid="b26-cm-95-229" ref-type="bibr">26</xref>].</p><p>Despite the fact that Breslow index has proven to have a high prognostic significance in numerous clinical trials, there are still cases of thin melanomas that metastasize and thick melanomas with good evolution and long-term survival. Therefore, for thin melanomas, identifying other factors that could provide information about the prognosis of the disease is essential.</p><p>A large German study conducted on 12,728 patients found that tumor thickness, age at the time of diagnosis, gender, subtype and location of the tumor are independent prognostic factors. Among these, tumor thickness has the strongest significance [<xref rid="b1-cm-95-229" ref-type="bibr">1</xref>].</p><p>Moreover, a Swedish study with more than 15 years of follow-up data, conducted on 13,026 patients with stage T1 melanoma, showed that tumor thickness, Clark level of invasion and ulceration confer an independent prognostic value and that the prognostic role of the Breslow index decreases when the tumor is ulcerated [<xref rid="b27-cm-95-229" ref-type="bibr">27</xref>].</p></sec><sec><title>Clark&#x02019;s level</title><p>Since 1969 Clark and his collaborators had found a link between level of tumor invasion and prognosis of patients with cutaneous melanoma. Clark&#x02019;s classification includes five stages according to the histological penetration depths of the tumor cell, as follows: level I &#x02013; involves only epidermis and corresponds to melanoma in situ, level II &#x02013; invasion of papillary dermis, level III &#x02013; invasion up to the interface between the papillary and the reticular dermis, level IV &#x02013; invasion of reticular dermis and level V &#x02013; invasion of subcutaneous tissue. Clark and his collaborators showed a median survival time of 6.83 years for the patients with level II of invasion and 3.5 years for the level V [<xref rid="b28-cm-95-229" ref-type="bibr">28</xref>].</p><p>Many studies have shown an inverse correlation between the depth of tumor invasion and patient survival [<xref rid="b29-cm-95-229" ref-type="bibr">29</xref>&#x02013;<xref rid="b31-cm-95-229" ref-type="bibr">31</xref>].</p><p>Some studies have shown that the prognostic significance of Clark index is not as strong compared to Breslow thickness [<xref rid="b26-cm-95-229" ref-type="bibr">26</xref>,<xref rid="b32-cm-95-229" ref-type="bibr">32</xref>] and others have shown that it is an independent prognostic factor only for thin melanomas (&#x02264;1 mm) [<xref rid="b6-cm-95-229" ref-type="bibr">6</xref>,<xref rid="b33-cm-95-229" ref-type="bibr">33</xref>,<xref rid="b34-cm-95-229" ref-type="bibr">34</xref>].</p><p>The 6<sup>th</sup> (2001) American Joint Committee on Cancer (AJCC) melanoma staging guidelines used Clark level of invasion and ulceration in addition to tumor Breslow thickness to subdivide thin melanoma as T1a or T1b [<xref rid="b35-cm-95-229" ref-type="bibr">35</xref>].</p><p>In the 7<sup>th</sup> edition (2009) of the AJCC classification, Clark level has been replaced by mitotic rate for stratification of primary tumors in the T1 stage [<xref rid="b36-cm-95-229" ref-type="bibr">36</xref>]. Thereafter, an increase in the number of T1a melanoma cases was observed [<xref rid="b37-cm-95-229" ref-type="bibr">37</xref>,<xref rid="b38-cm-95-229" ref-type="bibr">38</xref>]. This modification led to changes in the clinical approach with a different use of the sentinel lymph node biopsy (SLNB) [<xref rid="b38-cm-95-229" ref-type="bibr">38</xref>]. Current National Comprehensive Cancer Network Guidelines recommend performing SLNB in patients with tumor thickness between 0.76 and 1 mm if they associate either ulceration or 1 or more mitoses per mm<sup>2</sup> [<xref rid="b5-cm-95-229" ref-type="bibr">5</xref>].</p></sec><sec><title>Radial and vertical growth phase</title><p>Gimotty et al. demonstrated by multivariate analysis that the vertical growth phase confers an important predictive significance for the risk of metastasis at 10-year follow-up and carries a 42 times higher risk of metastasis than the radial growth phase tumors [<xref rid="b22-cm-95-229" ref-type="bibr">22</xref>].</p></sec><sec><title>Ulceration</title><p>Ulceration is defined as the epithelial disruption over its entire thickness and appears to be due to tumor ischemia that occurs with rapid tumor growth [<xref rid="b39-cm-95-229" ref-type="bibr">39</xref>]. This suggests that ulceration is more likely to occur in more aggressive tumors [<xref rid="b6-cm-95-229" ref-type="bibr">6</xref>].</p><p>Many studies have shown by multivariate analysis that the presence of tumor ulceration correlates with decreased overall survival [<xref rid="b33-cm-95-229" ref-type="bibr">33</xref>,<xref rid="b39-cm-95-229" ref-type="bibr">39</xref>] but also with the risk of relapse of melanoma patients [<xref rid="b5-cm-95-229" ref-type="bibr">5</xref>,<xref rid="b40-cm-95-229" ref-type="bibr">40</xref>].</p><p>It has been observed that the presence and prognostic role of ulceration is influenced by tumor thickness and that its incidence increases with a higher Breslow index. One study found a 12.5% incidence of ulceration in melanomas with tumor thickness less than 0.75 mm and 72.5% in melanomas thicker than 4 mm [<xref rid="b41-cm-95-229" ref-type="bibr">41</xref>].</p></sec><sec><title>Mitotic tumor rate</title><p>Numerous investigators have shown the prognostic value of mitotic tumor rate in patients with cutaneous melanoma. Several studies have proven that the mitotic rate has an independent prognostic value and also it is the most important prognostic factor for survival after Breslow tumor thickness [<xref rid="b3-cm-95-229" ref-type="bibr">3</xref>,<xref rid="b36-cm-95-229" ref-type="bibr">36</xref>,<xref rid="b42-cm-95-229" ref-type="bibr">42</xref>].</p><p>Barnhill and colleagues have shown that a mitotic index of 1&#x02013;6 mitoses/mm<sup>2</sup> increases the risk of mortality at 5 years by 8 times whereas a mitotic rate of more than 6 mitoses/mm<sup>2</sup> increases the mortality at 5 years by 11 times [<xref rid="b43-cm-95-229" ref-type="bibr">43</xref>].</p><p>In 2009 the AJCC included the mitotic rate in the melanoma TNM staging system for its independent predictive value of survival to subclassify T stage into T1a and T1b [<xref rid="b37-cm-95-229" ref-type="bibr">37</xref>].</p><p>However, in the current (8<sup>th</sup>) edition of AJCC staging system, the mitotic rate was removed from the staging criteria because it was concluded that the use of 0.8 mm cut point for stratification of T1 tumors is more strongly associated with the prognosis of the disease. However, that should be further calculated and recorded in the histological reports (<xref rid="tI-cm-95-229" ref-type="table">Table I</xref>) [<xref rid="b44-cm-95-229" ref-type="bibr">44</xref>].</p><p>Caldarella and colleagues showed that the most significant correlation with survival was at least 1 mitosis/mm<sup>2</sup> [<xref rid="b38-cm-95-229" ref-type="bibr">38</xref>].</p><p>In a recent retrospective study, investigators revealed that mitotic rate is the strongest predictor of survival after positive sentinel lymph node biopsy [<xref rid="b2-cm-95-229" ref-type="bibr">2</xref>]. Another large study concluded that mitotic rate is an independent predictor for survival [<xref rid="b45-cm-95-229" ref-type="bibr">45</xref>].</p></sec><sec><title>Regression</title><p>Histological regression can be found in 10 to 35% of melanomas [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>] and is defined as the replacement of tumor cells with fibrous tissue, inflammatory cells, neoformation vessels and melanophages. It is considered to be the result of the interaction between the tumor cells and the host&#x02019;s immune system via TILs (TILs - tumor infiltrating lymphocytes) [<xref rid="b6-cm-95-229" ref-type="bibr">6</xref>,<xref rid="b39-cm-95-229" ref-type="bibr">39</xref>,<xref rid="b46-cm-95-229" ref-type="bibr">46</xref>,<xref rid="b47-cm-95-229" ref-type="bibr">47</xref>].</p><p>Some authors believe that thin melanomas that showed regression and had a poor prognosis were initially thick melanomas and had a significant regression area in the past [<xref rid="b48-cm-95-229" ref-type="bibr">48</xref>].</p><p>Clark and coworkers thought that regression gives a poor prognosis, especially in thin melanomas in which the primary lesion regresses by more than 75% [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>,<xref rid="b49-cm-95-229" ref-type="bibr">49</xref>]. It has long been considered a negative prognostic factor due to the assumption that it could affect the correct assessment of Breslow&#x02019;s tumor thickness [<xref rid="b36-cm-95-229" ref-type="bibr">36</xref>,<xref rid="b50-cm-95-229" ref-type="bibr">50</xref>]. More recently, histological regression has been associated with a favorable prognosis. Two meta-analyses showed that tumor regression was associated with a low risk of lymph node metastases [<xref rid="b51-cm-95-229" ref-type="bibr">51</xref>] and a favorable prognosis [<xref rid="b52-cm-95-229" ref-type="bibr">52</xref>,<xref rid="b53-cm-95-229" ref-type="bibr">53</xref>].</p><p>This may be due to the fact that histologic regression is correlated with an early activation of the immune system. Despite this, there are no data in the literature to demonstrate the predictive role of immunotherapy response. However, it has been shown that there are similarities between the immune infiltrate from tumor regression and vitiligo-like reaction produced by immunotherapy and target therapy [<xref rid="b53-cm-95-229" ref-type="bibr">53</xref>].</p><p>In a recent study of thin melanomas, the authors showed low expression of CEACAM1 (CEACAM1- carcinoembryonic antigen-related cell adhesion molecule 1) in the tumor regression area. CEACAM1 is a key molecule that is associated with increased invasion and tumor progression in melanoma. This could strengthen the hypothesis that histological regression is rather a favorable prognostic factor in melanoma [<xref rid="b54-cm-95-229" ref-type="bibr">54</xref>].</p></sec><sec><title>Tumor-infiltrating lymphocytes (TILs)</title><p>Nowadays, the role of the host immune response against the development of melanoma is much more debated and it is believed that TILs have a key role in this process [<xref rid="b55-cm-95-229" ref-type="bibr">55</xref>]. Several studies have shown that the absence of TILs has an independent predictive role for the occurrence of lymph node or regional metastases.</p><p>For example, a study of 887 patients who underwent sentinel lymph node mapping showed that the absence of TILs was an independent predictive factor, in addition to tumor thickness, ulceration, and male sex. The absence of tumor infiltrate gives a 26.2% probability of developing lymph node metastases compared to a 3.9% probability of positive SLNB for melanomas with brisk infiltrate [<xref rid="b56-cm-95-229" ref-type="bibr">56</xref>].</p><p>Other factors with prognostic significance for melanoma patients are microscopic satellites [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>], tumor lymphangiogenesis [<xref rid="b57-cm-95-229" ref-type="bibr">57</xref>], vascular invasion, angiotropism, neurotropism, cellular atypia or the association with melanocytic nevus. The presence of microscopic satellites seems to suggest the existence of lymphatic metastases. [<xref rid="b11-cm-95-229" ref-type="bibr">11</xref>]. Some authors consider that tumor lymphangiogenesis is the strongest predictor for SLNB positivity. It might have even greater prognostic value than tumor thickness [<xref rid="b57-cm-95-229" ref-type="bibr">57</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Biological behavior and prognostic factors for primary cutaneous melanomas are still debatable. We reviewed in this article some important clinical and histological parameters with prognostic value in melanoma patients. These factors are conventional and are found in histopathology reports. Breslow tumor thickness remains the strongest prognostic factor for melanoma in general. However, for thin melanomas, other morphological, biological or molecular parameters with a predictive role on survival are needed. Currently, only Clark invasion index and ulceration have proven their prognostic value in this type of melanoma.</p><p>More studies are needed to analyze the prognostic role for other parameters such as tumor regression, tumor mitotic rate or tumor-infiltrating lymphocytes activity. Representing most of the melanomas, optimization of diagnosis and staging of thin melanomas has become particularly challenging at present.</p></sec></body><back><ref-list><title>References</title><ref id="b1-cm-95-229"><label>1</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leiter</surname><given-names>U</given-names></name><name><surname>Buettner</surname><given-names>PG</given-names></name><name><surname>Eigentler</surname><given-names>TK</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name></person-group>
<article-title>Prognostic factors of thin cutaneous melanoma: an analysis of the Central Malignant Melanoma Registry of the German Dermatological society</article-title>
<source>J Clin Oncol</source>
<year>2004</year>
<volume>22</volume>
<fpage>3660</fpage>
<lpage>3667</lpage>
<pub-id pub-id-type="pmid">15302905</pub-id></element-citation></ref><ref id="b2-cm-95-229"><label>2</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Namikawa</surname><given-names>K</given-names></name><name><surname>Aung</surname><given-names>PP</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Milton</surname><given-names>DR</given-names></name><name><surname>Prieto</surname><given-names>VG</given-names></name></person-group>
<article-title>Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center</article-title>
<source>Cancer Med</source>
<year>2018</year>
<volume>7</volume>
<fpage>583</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">29464914</pub-id></element-citation></ref><ref id="b3-cm-95-229"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hieken</surname><given-names>TJ</given-names></name><name><surname>Grotz</surname><given-names>TE</given-names></name><name><surname>Comfere</surname><given-names>NI</given-names></name><name><surname>Inselman</surname><given-names>JW</given-names></name><name><surname>Habermann</surname><given-names>EB</given-names></name></person-group>
<article-title>The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma</article-title>
<source>Melanoma Res</source>
<year>2015</year>
<volume>25</volume>
<fpage>157</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">25647736</pub-id></element-citation></ref><ref id="b4-cm-95-229"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dye</surname><given-names>DE</given-names></name><name><surname>Medic</surname><given-names>S</given-names></name><name><surname>Ziman</surname><given-names>M</given-names></name><name><surname>Coombe</surname><given-names>DR</given-names></name></person-group>
<article-title>Melanoma biomolecules: independently identified but functionally intertwined</article-title>
<source>Front Oncol</source>
<year>2013</year>
<volume>3</volume>
<fpage>252</fpage>
<pub-id pub-id-type="pmid">24069584</pub-id></element-citation></ref><ref id="b5-cm-95-229"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karakousis</surname><given-names>G</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Bartlett</surname><given-names>EK</given-names></name><name><surname>Sim</surname><given-names>MS</given-names></name><name><surname>Neuwirth</surname><given-names>MG</given-names></name><name><surname>Fraker</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis</article-title>
<source>Ann Surg Oncol</source>
<year>2017</year>
<volume>24</volume>
<fpage>952</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="pmid">27807729</pub-id></element-citation></ref><ref id="b6-cm-95-229"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Payette</surname><given-names>MJ</given-names></name><name><surname>Katz</surname><given-names>M</given-names><suffix>3rd</suffix></name><name><surname>Grant-Kels</surname><given-names>JM</given-names></name></person-group>
<article-title>Melanoma prognostic factors found in the dermatopathology report</article-title>
<source>Clin Dermatol</source>
<year>2009</year>
<volume>27</volume>
<fpage>53</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="pmid">19095154</pub-id></element-citation></ref><ref id="b7-cm-95-229"><label>7</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Paradela</surname><given-names>S</given-names></name><name><surname>Fonseca</surname><given-names>E</given-names></name><name><surname>Pita-Fern&#x000e1;ndez</surname><given-names>S</given-names></name><name><surname>Kantrow</surname><given-names>SM</given-names></name><name><surname>Diwan</surname><given-names>AH</given-names></name><name><surname>Herzog</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 patients</article-title>
<source>Cancer</source>
<year>2010</year>
<volume>116</volume>
<fpage>4334</fpage>
<lpage>4344</lpage>
<pub-id pub-id-type="pmid">20549825</pub-id></element-citation></ref><ref id="b8-cm-95-229"><label>8</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Egger</surname><given-names>ME</given-names></name><name><surname>Stepp</surname><given-names>LO</given-names></name><name><surname>Callender</surname><given-names>GG</given-names></name><name><surname>Quillo</surname><given-names>AR</given-names></name><name><surname>Martin</surname><given-names>RC</given-names><suffix>2nd</suffix></name><name><surname>Scoggins</surname><given-names>CR</given-names></name><etal/></person-group>
<article-title>Outcomes and prognostic factors in superficial spreading melanoma</article-title>
<source>Am J Surg</source>
<year>2013</year>
<volume>206</volume>
<fpage>861</fpage>
<lpage>868</lpage>
<comment>discussion 867&#x02013;868</comment>
<pub-id pub-id-type="pmid">24124662</pub-id></element-citation></ref><ref id="b9-cm-95-229"><label>9</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pi&#x000f1;ero-Madrona</surname><given-names>A</given-names></name><name><surname>Ruiz-Merino</surname><given-names>G</given-names></name><name><surname>Cerezuela Fuentes</surname><given-names>P</given-names></name><name><surname>Mart&#x000ed;nez-Barba</surname><given-names>E</given-names></name><name><surname>Rodr&#x000ed;guez-L&#x000f3;pez</surname><given-names>JN</given-names></name><name><surname>Cabezas-Herrera</surname><given-names>J</given-names></name></person-group>
<article-title>Mitotic rate as an important prognostic factor in cutaneous malignant melanoma</article-title>
<source>Clin Transl Oncol</source>
<year>2019</year>
<volume>21</volume>
<fpage>1348</fpage>
<lpage>1356</lpage>
<pub-id pub-id-type="pmid">30783917</pub-id></element-citation></ref><ref id="b10-cm-95-229"><label>10</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chao</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>RC</given-names><suffix>2nd</suffix></name><name><surname>Ross</surname><given-names>MI</given-names></name><name><surname>Reintgen</surname><given-names>DS</given-names></name><name><surname>Edwards</surname><given-names>MJ</given-names></name><name><surname>Noyes</surname><given-names>RD</given-names></name><etal/></person-group>
<article-title>Correlation between prognostic factors and increasing age in melanoma</article-title>
<source>Ann Surg Oncol</source>
<year>2004</year>
<volume>11</volume>
<fpage>259</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="pmid">14993020</pub-id></element-citation></ref><ref id="b11-cm-95-229"><label>11</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tejera-Vaquerizo</surname><given-names>A</given-names></name><name><surname>Sol&#x000ed;s-Garc&#x000ed;a</surname><given-names>E</given-names></name><name><surname>R&#x000ed;os-Mart&#x000ed;n</surname><given-names>JJ</given-names></name><name><surname>Moreno-Ram&#x000ed;rez</surname><given-names>D</given-names></name></person-group>
<article-title>Primary cutaneous melanoma: prognostic factors not included in the classification of the American Joint Committee on Cancer</article-title>
<source>Actas Dermosifiliogr</source>
<year>2011</year>
<volume>102</volume>
<fpage>255</fpage>
<lpage>263</lpage>
<pub-id pub-id-type="pmid">21440241</pub-id></element-citation></ref><ref id="b12-cm-95-229"><label>12</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clary</surname><given-names>BM</given-names></name><name><surname>Brady</surname><given-names>MS</given-names></name><name><surname>Lewis</surname><given-names>JJ</given-names></name><name><surname>Coit</surname><given-names>DG</given-names></name></person-group>
<article-title>Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence</article-title>
<source>Ann Surg</source>
<year>2001</year>
<volume>233</volume>
<fpage>250</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="pmid">11176132</pub-id></element-citation></ref><ref id="b13-cm-95-229"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Busam</surname><given-names>KJ</given-names></name><name><surname>Murali</surname><given-names>R</given-names></name><name><surname>Pulitzer</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>SW</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Shaw</surname><given-names>HM</given-names></name><etal/></person-group>
<article-title>Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas</article-title>
<source>Am J Surg Pathol</source>
<year>2009</year>
<volume>33</volume>
<fpage>1386</fpage>
<lpage>1395</lpage>
<pub-id pub-id-type="pmid">19609204</pub-id></element-citation></ref><ref id="b14-cm-95-229"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>KG</given-names></name></person-group>
<article-title>Trends in pediatric melanoma mortality in the United States, 1968 through 2004</article-title>
<source>Dermatol Surg</source>
<year>2008</year>
<volume>34</volume>
<fpage>152</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="pmid">18093205</pub-id></element-citation></ref><ref id="b15-cm-95-229"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Youl</surname><given-names>P</given-names></name><name><surname>Aitken</surname><given-names>J</given-names></name><name><surname>Hayward</surname><given-names>N</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Lassam</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Melanoma in adolescents: a case-control study of risk factors in Queensland, Australia</article-title>
<source>Int J Cancer</source>
<year>2002</year>
<volume>98</volume>
<fpage>92</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">11857391</pub-id></element-citation></ref><ref id="b16-cm-95-229"><label>16</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaddu</surname><given-names>S</given-names></name><name><surname>Smolle</surname><given-names>J</given-names></name><name><surname>Zenahlik</surname><given-names>P</given-names></name><name><surname>Hofmann-Wellenhof</surname><given-names>R</given-names></name><name><surname>Kerl</surname><given-names>H</given-names></name></person-group>
<article-title>Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis</article-title>
<source>Melanoma Res</source>
<year>2002</year>
<volume>12</volume>
<fpage>271</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="pmid">12140384</pub-id></element-citation></ref><ref id="b17-cm-95-229"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ra</surname><given-names>JH</given-names></name><name><surname>McMasters</surname><given-names>KM</given-names></name><name><surname>Spitz</surname><given-names>FR</given-names></name></person-group>
<article-title>Should all melanoma patients undergo sentinel lymph node biopsy?</article-title>
<source>Curr Opin Oncol</source>
<year>2006</year>
<volume>18</volume>
<fpage>185</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">16462189</pub-id></element-citation></ref><ref id="b18-cm-95-229"><label>18</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>P</given-names></name><name><surname>Bertz</surname><given-names>J</given-names></name><name><surname>Burg</surname><given-names>G</given-names></name><name><surname>d&#x02019;Hoedt</surname><given-names>B</given-names></name><name><surname>Drepper</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients</article-title>
<source>Cancer</source>
<year>1995</year>
<volume>75</volume>
<fpage>2484</fpage>
<lpage>2491</lpage>
<pub-id pub-id-type="pmid">7736392</pub-id></element-citation></ref><ref id="b19-cm-95-229"><label>19</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Travers</surname><given-names>RL</given-names></name><name><surname>Sober</surname><given-names>AJ</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names><suffix>Jr</suffix></name><name><surname>Barnhill</surname><given-names>RL</given-names></name><name><surname>Duncan</surname><given-names>LM</given-names></name></person-group>
<article-title>Increased thickness of pregnancy-associated melanoma</article-title>
<source>Br J Dermatol</source>
<year>1995</year>
<volume>132</volume>
<fpage>876</fpage>
<lpage>883</lpage>
<pub-id pub-id-type="pmid">7662565</pub-id></element-citation></ref><ref id="b20-cm-95-229"><label>20</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lindholm</surname><given-names>C</given-names></name><name><surname>Andersson</surname><given-names>R</given-names></name><name><surname>Dufmats</surname><given-names>M</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Ingvar</surname><given-names>C</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Invasive cutaneous malignant melanoma in Sweden, 1990&#x02013;1999: A prospective, population-based study of survival and prognostic factors</article-title>
<source>Cancer</source>
<year>2004</year>
<volume>101</volume>
<fpage>2067</fpage>
<lpage>2078</lpage>
<pub-id pub-id-type="pmid">15372475</pub-id></element-citation></ref><ref id="b21-cm-95-229"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Massi</surname><given-names>D</given-names></name><name><surname>Franchi</surname><given-names>A</given-names></name><name><surname>Borgognoni</surname><given-names>L</given-names></name><name><surname>Reali</surname><given-names>UM</given-names></name><name><surname>Santucci</surname><given-names>M</given-names></name></person-group>
<article-title>Thin cutaneous malignant melanomas (&#x0003c; or =1.5 mm): identification of risk factors indicative of progression</article-title>
<source>Cancer</source>
<year>1999</year>
<volume>85</volume>
<fpage>1067</fpage>
<lpage>1076</lpage>
<pub-id pub-id-type="pmid">10091790</pub-id></element-citation></ref><ref id="b22-cm-95-229"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Guerry</surname><given-names>DP</given-names></name><name><surname>Ming</surname><given-names>ME</given-names></name><name><surname>Elenitsas</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Czerniecki</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging</article-title>
<source>J Clin Oncol</source>
<year>2004</year>
<volume>22</volume>
<fpage>3668</fpage>
<lpage>3676</lpage>
<pub-id pub-id-type="pmid">15302909</pub-id></element-citation></ref><ref id="b23-cm-95-229"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKinnon</surname><given-names>JG</given-names></name><name><surname>Yu</surname><given-names>XQ</given-names></name><name><surname>McCarthy</surname><given-names>WH</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name></person-group>
<article-title>Prognosis for patients with thin cutaneous melanoma: long-term survival data from the New South Wales Central Cancer Registry and the Sydney Melanoma Unit</article-title>
<source>Cancer</source>
<year>2003</year>
<volume>98</volume>
<fpage>1223</fpage>
<lpage>1231</lpage>
<pub-id pub-id-type="pmid">12973846</pub-id></element-citation></ref><ref id="b24-cm-95-229"><label>24</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lachiewicz</surname><given-names>AM</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name><name><surname>Wiggins</surname><given-names>CL</given-names></name><name><surname>Thomas</surname><given-names>NE</given-names></name></person-group>
<article-title>Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program</article-title>
<source>Arch Dermatol</source>
<year>2008</year>
<volume>144</volume>
<fpage>515</fpage>
<lpage>521</lpage>
<pub-id pub-id-type="pmid">18427046</pub-id></element-citation></ref><ref id="b25-cm-95-229"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meier</surname><given-names>F</given-names></name><name><surname>Will</surname><given-names>S</given-names></name><name><surname>Ellwanger</surname><given-names>U</given-names></name><name><surname>Schlagenhauff</surname><given-names>B</given-names></name><name><surname>Schittek</surname><given-names>B</given-names></name><name><surname>Rassner</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Metastatic pathways and time courses in the orderly progression of cutaneous melanoma</article-title>
<source>Br J Dermatol</source>
<year>2002</year>
<volume>147</volume>
<fpage>62</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">12100186</pub-id></element-citation></ref><ref id="b26-cm-95-229"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Breslow</surname><given-names>A</given-names></name></person-group>
<article-title>Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma</article-title>
<source>Ann Surg</source>
<year>1970</year>
<volume>172</volume>
<fpage>902</fpage>
<lpage>908</lpage>
<pub-id pub-id-type="pmid">5477666</pub-id></element-citation></ref><ref id="b27-cm-95-229"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lyth</surname><given-names>J</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Ingvar</surname><given-names>C</given-names></name><name><surname>M&#x000e5;nsson-Brahme</surname><given-names>E</given-names></name><name><surname>Naredi</surname><given-names>P</given-names></name><name><surname>Stierner</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark&#x02019;s level of invasion: results of a population-based study from the Swedish Melanoma Register</article-title>
<source>Br J Dermatol</source>
<year>2013</year>
<volume>168</volume>
<fpage>779</fpage>
<lpage>786</lpage>
<pub-id pub-id-type="pmid">23066913</pub-id></element-citation></ref><ref id="b28-cm-95-229"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>From</surname><given-names>L</given-names></name><name><surname>Bernardino</surname><given-names>EA</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names></name></person-group>
<article-title>The histogenesis and biologic behavior of primary human malignant melanomas of the skin</article-title>
<source>Cancer Res</source>
<year>1969</year>
<volume>29</volume>
<fpage>705</fpage>
<lpage>727</lpage>
<pub-id pub-id-type="pmid">5773814</pub-id></element-citation></ref><ref id="b29-cm-95-229"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>P</given-names></name><name><surname>Bertz</surname><given-names>J</given-names></name><name><surname>Burg</surname><given-names>G</given-names></name><name><surname>d&#x02019;Hoedt</surname><given-names>B</given-names></name><name><surname>Drepper</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Primary cutaneous melanoma. Prognostic classification of anatomic location</article-title>
<source>Cancer</source>
<year>1995</year>
<volume>75</volume>
<fpage>2492</fpage>
<lpage>2498</lpage>
<pub-id pub-id-type="pmid">7736393</pub-id></element-citation></ref><ref id="b30-cm-95-229"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morton</surname><given-names>DL</given-names></name><name><surname>Davtyan</surname><given-names>DG</given-names></name><name><surname>Wanek</surname><given-names>LA</given-names></name><name><surname>Foshag</surname><given-names>LJ</given-names></name><name><surname>Cochran</surname><given-names>AJ</given-names></name></person-group>
<article-title>Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness</article-title>
<source>Cancer</source>
<year>1993</year>
<volume>71</volume>
<fpage>3737</fpage>
<lpage>3743</lpage>
<pub-id pub-id-type="pmid">8490924</pub-id></element-citation></ref><ref id="b31-cm-95-229"><label>31</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>M&#x000e5;sb&#x000e4;ck</surname><given-names>A</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name><name><surname>Westerdahl</surname><given-names>J</given-names></name><name><surname>Ingvar</surname><given-names>C</given-names></name><name><surname>Jonsson</surname><given-names>N</given-names></name></person-group>
<article-title>Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review</article-title>
<source>Melanoma Res</source>
<year>2001</year>
<volume>11</volume>
<fpage>435</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="pmid">11595879</pub-id></element-citation></ref><ref id="b32-cm-95-229"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Murad</surname><given-names>TM</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Ingalls</surname><given-names>AL</given-names></name><name><surname>Halpern</surname><given-names>NB</given-names></name><name><surname>Maddox</surname><given-names>WA</given-names></name></person-group>
<article-title>A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark&#x02019;s and Breslow&#x02019;s staging methods</article-title>
<source>Ann Surg</source>
<year>1978</year>
<volume>188</volume>
<fpage>732</fpage>
<lpage>742</lpage>
<pub-id pub-id-type="pmid">736651</pub-id></element-citation></ref><ref id="b33-cm-95-229"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Reintgen</surname><given-names>DS</given-names></name><name><surname>Cascinelli</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system</article-title>
<source>J Clin Oncol</source>
<year>2001</year>
<volume>19</volume>
<fpage>3622</fpage>
<lpage>3634</lpage>
<pub-id pub-id-type="pmid">11504744</pub-id></element-citation></ref><ref id="b34-cm-95-229"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>H&#x000e4;ffner</surname><given-names>AC</given-names></name><name><surname>Garbe</surname><given-names>C</given-names></name><name><surname>Burg</surname><given-names>G</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>P</given-names></name><name><surname>Orfanos</surname><given-names>CE</given-names></name><name><surname>Rassner</surname><given-names>G</given-names></name></person-group>
<article-title>The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients</article-title>
<source>Br J Cancer</source>
<year>1992</year>
<volume>66</volume>
<fpage>856</fpage>
<lpage>861</lpage>
<pub-id pub-id-type="pmid">1419627</pub-id></element-citation></ref><ref id="b35-cm-95-229"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schuchter</surname><given-names>LM</given-names></name></person-group>
<article-title>Review of the 2001 AJCC staging system for cutaneous malignant melanoma</article-title>
<source>Curr Oncol Rep</source>
<year>2001</year>
<volume>3</volume>
<fpage>332</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="pmid">11389818</pub-id></element-citation></ref><ref id="b36-cm-95-229"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Byrd</surname><given-names>DR</given-names></name><etal/></person-group>
<article-title>Final version of 2009 AJCC melanoma staging and classification</article-title>
<source>J Clin Oncol</source>
<year>2009</year>
<volume>27</volume>
<fpage>6199</fpage>
<lpage>6206</lpage>
<pub-id pub-id-type="pmid">19917835</pub-id></element-citation></ref><ref id="b37-cm-95-229"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chu</surname><given-names>VH</given-names></name><name><surname>Tetzlaff</surname><given-names>MT</given-names></name><name><surname>Torres-Cabala</surname><given-names>CA</given-names></name><name><surname>Prieto</surname><given-names>VG</given-names></name><name><surname>Bassett</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Impact of the 2009 (7<sup>th</sup> Edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas</article-title>
<source>Biomed Res Int</source>
<year>2013</year>
<volume>2013</volume>
<fpage>898719</fpage>
<pub-id pub-id-type="pmid">24369020</pub-id></element-citation></ref><ref id="b38-cm-95-229"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caldarella</surname><given-names>A</given-names></name><name><surname>Fancelli</surname><given-names>L</given-names></name><name><surname>Manneschi</surname><given-names>G</given-names></name><name><surname>Chiarugi</surname><given-names>A</given-names></name><name><surname>Nardini</surname><given-names>P</given-names></name><name><surname>Crocetti</surname><given-names>E</given-names></name></person-group>
<article-title>How staging of thin melanoma is changed after the introduction of TNM 7<sup>th</sup> edition: a population-based analysis</article-title>
<source>J Cancer Res Clin Oncol</source>
<year>2016</year>
<volume>142</volume>
<fpage>73</fpage>
<lpage>76</lpage>
<pub-id pub-id-type="pmid">26113451</pub-id></element-citation></ref><ref id="b39-cm-95-229"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Crowson</surname><given-names>AN</given-names></name><name><surname>Magro</surname><given-names>CM</given-names></name><name><surname>Mihm</surname><given-names>MC</given-names></name></person-group>
<article-title>Prognosticators of melanoma, the melanoma report, and the sentinel lymph node</article-title>
<source>Mod Pathol</source>
<year>2006</year>
<volume>19</volume>
<issue>Suppl 2</issue>
<fpage>S71</fpage>
<lpage>S87</lpage>
<pub-id pub-id-type="pmid">16446717</pub-id></element-citation></ref><ref id="b40-cm-95-229"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lassau</surname><given-names>N</given-names></name><name><surname>Koscielny</surname><given-names>S</given-names></name><name><surname>Avril</surname><given-names>MF</given-names></name><name><surname>Margulis</surname><given-names>A</given-names></name><name><surname>Duvillard</surname><given-names>P</given-names></name><name><surname>De Baere</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Prognostic value of angiogenesis evaluated with high-frequency and color Doppler sonography for preoperative assessment of melanomas</article-title>
<source>AJR Am J Roentgenol</source>
<year>2002</year>
<volume>178</volume>
<fpage>1547</fpage>
<lpage>1551</lpage>
<pub-id pub-id-type="pmid">12034636</pub-id></element-citation></ref><ref id="b41-cm-95-229"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Balch</surname><given-names>CM</given-names></name><name><surname>Wilkerson</surname><given-names>JA</given-names></name><name><surname>Murad</surname><given-names>TM</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Ingalls</surname><given-names>AL</given-names></name><name><surname>Maddox</surname><given-names>WA</given-names></name></person-group>
<article-title>The prognostic significance of ulceration of cutaneous melanoma</article-title>
<source>Cancer</source>
<year>1980</year>
<volume>45</volume>
<fpage>3012</fpage>
<lpage>3017</lpage>
<pub-id pub-id-type="pmid">7388745</pub-id></element-citation></ref><ref id="b42-cm-95-229"><label>42</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Azzola</surname><given-names>MF</given-names></name><name><surname>Shaw</surname><given-names>HM</given-names></name><name><surname>Thompson</surname><given-names>JF</given-names></name><name><surname>Soong</surname><given-names>SJ</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Watson</surname><given-names>GF</given-names></name><etal/></person-group>
<article-title>Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center</article-title>
<source>Cancer</source>
<year>2003</year>
<volume>97</volume>
<fpage>1488</fpage>
<lpage>1498</lpage>
<pub-id pub-id-type="pmid">12627514</pub-id></element-citation></ref><ref id="b43-cm-95-229"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnhill</surname><given-names>RL</given-names></name><name><surname>Katzen</surname><given-names>J</given-names></name><name><surname>Spatz</surname><given-names>A</given-names></name><name><surname>Fine</surname><given-names>J</given-names></name><name><surname>Berwick</surname><given-names>M</given-names></name></person-group>
<article-title>The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma</article-title>
<source>J Cutan Pathol</source>
<year>2005</year>
<volume>32</volume>
<fpage>268</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="pmid">15769275</pub-id></element-citation></ref><ref id="b44-cm-95-229"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Scolyer</surname><given-names>RA</given-names></name><name><surname>Hess</surname><given-names>KR</given-names></name><name><surname>Sondak</surname><given-names>VK</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Ross</surname><given-names>MI</given-names></name><etal/></person-group>
<article-title>Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual</article-title>
<source>CA Cancer J Clin</source>
<year>2017</year>
<volume>67</volume>
<fpage>472</fpage>
<lpage>492</lpage>
<pub-id pub-id-type="pmid">29028110</pub-id></element-citation></ref><ref id="b45-cm-95-229"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evans</surname><given-names>JL</given-names></name><name><surname>Vidri</surname><given-names>RJ</given-names></name><name><surname>MacGillivray</surname><given-names>DC</given-names></name><name><surname>Fitzgerald</surname><given-names>TL</given-names></name></person-group>
<article-title>Tumor mitotic rate is an independent predictor of survival for nonmetastatic melanoma</article-title>
<source>Surgery</source>
<year>2018</year>
<volume>164</volume>
<fpage>589</fpage>
<lpage>593</lpage>
<pub-id pub-id-type="pmid">29929753</pub-id></element-citation></ref><ref id="b46-cm-95-229"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zettersten</surname><given-names>E</given-names></name><name><surname>Shaikh</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>R</given-names></name><name><surname>Kashani-Sabet</surname><given-names>M</given-names></name></person-group>
<article-title>Prognostic factors in primary cutaneous melanoma</article-title>
<source>Surg Clin North Am</source>
<year>2003</year>
<volume>83</volume>
<fpage>61</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">12691450</pub-id></element-citation></ref><ref id="b47-cm-95-229"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cartron</surname><given-names>AM</given-names></name><name><surname>Aldana</surname><given-names>PC</given-names></name><name><surname>Khachemoune</surname><given-names>A</given-names></name></person-group>
<article-title>Reporting regression in primary cutaneous melanoma. Part 1: history, histological criteria and pathogenesis</article-title>
<source>Clin Exp Dermatol</source>
<year>2021</year>
<volume>46</volume>
<fpage>28</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">32597504</pub-id></element-citation></ref><ref id="b48-cm-95-229"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gromet</surname><given-names>MA</given-names></name><name><surname>Epstein</surname><given-names>WL</given-names></name><name><surname>Blois</surname><given-names>MS</given-names></name></person-group>
<article-title>The regressing thin malignant melanoma: a distinctive lesion with metastatic potential</article-title>
<source>Cancer</source>
<year>1978</year>
<volume>42</volume>
<fpage>2282</fpage>
<lpage>2292</lpage>
<pub-id pub-id-type="pmid">719608</pub-id></element-citation></ref><ref id="b49-cm-95-229"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Elder</surname><given-names>DE</given-names></name><name><surname>Guerry</surname><given-names>D</given-names><suffix>4th</suffix></name><name><surname>Braitman</surname><given-names>LE</given-names></name><name><surname>Trock</surname><given-names>BJ</given-names></name><name><surname>Schultz</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Model predicting survival in stage I melanoma based on tumor progression</article-title>
<source>J Natl Cancer Inst</source>
<year>1989</year>
<volume>81</volume>
<fpage>1893</fpage>
<lpage>1904</lpage>
<pub-id pub-id-type="pmid">2593166</pub-id></element-citation></ref><ref id="b50-cm-95-229"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Slingluff</surname><given-names>CL</given-names><suffix>Jr</suffix></name><name><surname>Seigler</surname><given-names>HF</given-names></name></person-group>
<article-title>&#x0201c;Thin&#x0201d; malignant melanoma: risk factors and clinical management</article-title>
<source>Ann Plast Surg</source>
<year>1992</year>
<volume>28</volume>
<fpage>89</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">1642416</pub-id></element-citation></ref><ref id="b51-cm-95-229"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribero</surname><given-names>S</given-names></name><name><surname>Gualano</surname><given-names>MR</given-names></name><name><surname>Osella-Abate</surname><given-names>S</given-names></name><name><surname>Scaioli</surname><given-names>G</given-names></name><name><surname>Bert</surname><given-names>F</given-names></name><name><surname>Sanlorenzo</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Association of Histologic Regression in Primary Melanoma With Sentinel Lymph Node Status: A Systematic Review and Meta-analysis</article-title>
<source>JAMA Dermatol</source>
<year>2015</year>
<volume>151</volume>
<fpage>1301</fpage>
<lpage>1307</lpage>
<pub-id pub-id-type="pmid">26332402</pub-id></element-citation></ref><ref id="b52-cm-95-229"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gualano</surname><given-names>MR</given-names></name><name><surname>Osella-Abate</surname><given-names>S</given-names></name><name><surname>Scaioli</surname><given-names>G</given-names></name><name><surname>Marra</surname><given-names>E</given-names></name><name><surname>Bert</surname><given-names>F</given-names></name><name><surname>Faure</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis</article-title>
<source>Br J Dermatol</source>
<year>2018</year>
<volume>178</volume>
<fpage>357</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">28386936</pub-id></element-citation></ref><ref id="b53-cm-95-229"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ribero</surname><given-names>S</given-names></name></person-group>
<article-title>Histological regression in primary melanoma and drug-related immune reaction towards metastatic melanoma: Are they associated??</article-title>
<source>Med Hypotheses</source>
<year>2020</year>
<volume>143</volume>
<fpage>110019</fpage>
<pub-id pub-id-type="pmid">32645656</pub-id></element-citation></ref><ref id="b54-cm-95-229"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nichita</surname><given-names>L</given-names></name><name><surname>Zurac</surname><given-names>S</given-names></name><name><surname>Bastian</surname><given-names>A</given-names></name><name><surname>Stinga</surname><given-names>P</given-names></name><name><surname>Nedelcu</surname><given-names>R</given-names></name><name><surname>Brinzea</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Comparative analysis of CEACAM1 expression in thin melanomas with and without regression</article-title>
<source>Oncol Lett</source>
<year>2019</year>
<volume>17</volume>
<fpage>4149</fpage>
<lpage>4154</lpage>
<pub-id pub-id-type="pmid">30944609</pub-id></element-citation></ref><ref id="b55-cm-95-229"><label>55</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antohe</surname><given-names>M</given-names></name><name><surname>Nedelcu</surname><given-names>RI</given-names></name><name><surname>Nichita</surname><given-names>L</given-names></name><name><surname>Popp</surname><given-names>CG</given-names></name><name><surname>Cioplea</surname><given-names>M</given-names></name><name><surname>Brinzea</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Tumor infiltrating lymphocytes: The regulator of melanoma evolution</article-title>
<source>Oncol Lett</source>
<year>2019</year>
<volume>17</volume>
<fpage>4155</fpage>
<lpage>4161</lpage>
<pub-id pub-id-type="pmid">30944610</pub-id></element-citation></ref><ref id="b56-cm-95-229"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RC</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Panageas</surname><given-names>KS</given-names></name><name><surname>Busam</surname><given-names>KJ</given-names></name><name><surname>Brady</surname><given-names>MS</given-names></name></person-group>
<article-title>Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma</article-title>
<source>J Clin Oncol</source>
<year>2007</year>
<volume>25</volume>
<fpage>869</fpage>
<lpage>875</lpage>
<pub-id pub-id-type="pmid">17327608</pub-id></element-citation></ref><ref id="b57-cm-95-229"><label>57</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dadras</surname><given-names>SS</given-names></name><name><surname>Lange-Asschenfeldt</surname><given-names>B</given-names></name><name><surname>Velasco</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Muzikansky</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes</article-title>
<source>Mod Pathol</source>
<year>2005</year>
<volume>18</volume>
<fpage>1232</fpage>
<lpage>1242</lpage>
<pub-id pub-id-type="pmid">15803182</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="tI-cm-95-229"><label>Table I</label><caption><p>The 8<sup>th</sup> Edition of the American Joint Committee of Cancer (AJCC) Melanoma Staging System.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">T category</th><th valign="middle" align="center" rowspan="1" colspan="1">Tumor thickness</th><th valign="middle" align="center" rowspan="1" colspan="1">Ulceration</th></tr><tr><th colspan="3" valign="middle" align="left" rowspan="1">
<hr/></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1"><bold>Tx</bold> -The thickness of the primary tumor cannot be assessed</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><bold>T0</bold> - No evidence of primary tumor</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1"><bold>Tis -</bold> Melanoma in situ</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="middle" align="center" rowspan="1" colspan="1">Not applicable</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T1</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02264; 1.0 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Unknown/unspecified</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T1a</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.8 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">No ulceration</td></tr><tr><td valign="middle" rowspan="2" align="center" colspan="1">T1b</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c; 0.8 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">With ulceration</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">0.8&#x02013;1 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">With/without ulceration</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T2</td><td valign="middle" align="center" rowspan="1" colspan="1">1&#x02013;2 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Unknown/unspecified</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T2a</td><td valign="middle" rowspan="2" align="center" colspan="1">1&#x02013;2 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Without ulceration</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T2b</td><td valign="middle" align="center" rowspan="1" colspan="1">With ulceration</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T3</td><td valign="middle" align="center" rowspan="1" colspan="1">2&#x02013;4 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Unknown/unspecified</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T3a</td><td valign="middle" rowspan="2" align="center" colspan="1">2&#x02013;4 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Without ulceration</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T3b</td><td valign="middle" align="center" rowspan="1" colspan="1">With ulceration</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;T4</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003e; 4 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Unknown/unspecified</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4a</td><td valign="middle" rowspan="2" align="center" colspan="1">&#x0003e; 4 mm</td><td valign="middle" align="center" rowspan="1" colspan="1">Without ulceration</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">T4b</td><td valign="middle" align="center" rowspan="1" colspan="1">With ulceration</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>N category</bold>
</td><td colspan="2" valign="middle" align="center" rowspan="1">
<bold>The number of affected regional lymph nodes</bold>
</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">Nx</td><td colspan="2" valign="middle" align="left" rowspan="1">Lymph nodes cannot be evaluated</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N0</td><td colspan="2" valign="middle" align="left" rowspan="1">No regional metastases detected</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N1</td><td colspan="2" valign="middle" align="left" rowspan="1">Single lymph node metastases or transit/satellite metastases without lymph node metastasis</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N2</td><td colspan="2" valign="middle" align="left" rowspan="1">Metastases in two or three nodes or metastases in transit/satellites with metastasis in one node</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;N3</td><td colspan="2" valign="middle" align="left" rowspan="1">Metastases in four or more lymph nodes or transit metastases/satellites with metastasis in two or more nodes or any number of lymph node metastases with/without transit/satellite metastases</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">
<bold>M category</bold>
</td><td colspan="2" valign="middle" align="center" rowspan="1">
<bold>Anatomical location</bold>
</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">M0</td><td colspan="2" valign="middle" align="center" rowspan="1">No distant metastases detected</td></tr><tr><td colspan="3" valign="middle" align="left" rowspan="1">
<hr/></td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">M1</td><td colspan="2" valign="middle" align="center" rowspan="1">Distant metastasis detected</td></tr></tbody></table></table-wrap></floats-group></article>
